Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Achaogen, Inc. (Details) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Sep. 30, 2014 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) Drug	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2006 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned		$ 160,349	$ 110,927	$ 38,470	$ 36,874	$ 51,571	$ 49,121	$ 120,428	$ 62,583	$ 346,620	$ 283,703	$ 214,161
Achaogen, Inc. [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront fee in the form of equity securities													$ 1,500
Number of drugs to be developed and commercialized | Drug										2
Maximum amount of payments receivable for development, regulatory and commercialization milestones		49,300								$ 49,300
Cumulative payments received		7,000								7,000
Milestone payment earned	$ 4,000
Next prospective milestone		$ 7,500								7,500
Revenue earned										$ 0	$ 0	4,000
Net proceeds from sale of stock												$ 1,300